• 1
    World Health Organization. World health statistics annual 1995. Geneva: WHO, 1996.
  • 2
    Schmidt JD, Mettlin CJ, Natarajan N, et al. Trends in patterns of care for prostatic cancer, 1974–1983: results of surveys by the American College of Surgeons. J Urol 1986;136: 41621.
  • 3
    Catalona WJ, Richie JP, Ahmann FR. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151: 128390.
  • 4
    Mettlin C, Lee F, Drago J, et al. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991;67: 294958.
  • 5
    Carter HB, Epstein JI, Chan DW, et al. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277: 14756.
  • 6
    Kramer BS, Gohagan J, Prorok PC, et al. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993;71: 58993.
  • 7
    Auvinen A, Rietbergen JBW, Denis LJ, et al. International Prostate Cancer Screening Trial Evaluation Group. Prospective evaluation plan for randomized trials of prostate cancer screening. J Med Screening 1996;3: 97104.
  • 8
    Schröder FH, Maas P van der, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998;90: 181723.
  • 9
    Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349: 90610.
  • 10
    Labrie F, Candas B, Cusan L, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47: 2127.
  • 11
    Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis from the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38: 8391.
  • 12
    Boer R, Schröder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction [letter]. Prostate 1999;40: 1301.
  • 13
    Parkin DM. Cancer incidence in five continents, vols. VI, VII. WHO, IARC, Lyon: IARC 1992, 1997.
  • 14
    Stephenson RA, Smart CR, Mineau GP, et al. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence—data from the Utah Cancer Registry. Cancer 1995;77: 13428.
  • 15
    Smart CR. Prostate cancer facts and fiction [editorial]. J Surg Oncol 1997; 66: 2239.
  • 16
    Boer R, Warmerdam P, Koning Hde, van Oortmarssen G. Extra incidence caused by mammographic screening [letter]. Lancet 1994;343: 979.
  • 17
    Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995;274: 14459.
  • 18
    Stenman U-H, Hakama M, Knekt P, et al. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344: 15948.
  • 19
    Parkes C, Wald NJ, Murphy P, et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 1995;311: 3403.
  • 20
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273: 28994.
  • 21
    Reissigl A, Horninger W, Fink K, et al. Prostate carcinoma screening in the county of Tyrol, Austria. Cancer 1997;80: 181829.
  • 22
    Finnish Cancer Registry—Institute for Statistical and Epidemiological Cancer Research Cancer incidence in Finland 1995. Cancer Statistics of the National Research and Development Center for Welfare and Health. Helsinki: Cancer Society of Finland Publication No. 58; 1997.
  • 23
    Essink-Bot M-L, Koning HJde, Nijs HGT, et al. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998;90: 92531.